Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 11, 2022JAMAOpen Access

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Implication

Randomized trial demonstrates greater weight reduction with weekly semaglutide versus daily liraglutide in adults with obesity, indicating superior efficacy for weight management.

Key Points

  • To compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide (2.4 mg) versus once-daily subcutaneous liraglutide (3.0 mg), alongside diet and physical activity, in adults with overweight or obesity without diabetes.
  • Randomized, open-label, 68-week, phase 3b trial conducted across 19 US sites from September 2019 to May 2021 (NCT04074161).
  • Enrolled 338 adults with BMI ≥30, or ≥27 with weight-related comorbidities, randomized 3:1:3:1 to weekly semaglutide 2.4 mg (n=126), daily liraglutide 3.0 mg (n=127), or matched placebos pooled (n=85), combined with lifestyle interventions.
  • Mean weight change from baseline at week 68 was -15.8% with semaglutide versus -6.4% with liraglutide (difference: -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001), compared to -1.9% with pooled placebo.
  • Participants receiving semaglutide had significantly higher odds of achieving weight loss thresholds: ≥10% loss (70.9% vs 25.6%; OR 6.3 [95% CI, 3.5–11.2]; P < .001), ≥15% loss (55.6% vs 12.0%; OR 7.9 [95% CI, 4.1–15.4]; P < .001), and ≥20% loss (38.5% vs 6.0%; OR 8.2 [95% CI, 3.5–19.1]; P < .001).
  • Treatment discontinuation occurred in 13.5% of semaglutide participants and 27.6% of liraglutide participants, while gastrointestinal adverse events occurred in 84.1% and 82.7%, respectively.

Cite This Study

A 2022 study studied this question.

synapsesocial.com/papers/6a7d08423575152c8237cc3chttps://doi.org/10.1001/jama.2021.23619
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide2011 · 765 citations
  2. 2Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity2021 · 1,410 citations
  3. 3Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status2014 · 189 citations
  4. 4Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide2015 · 1,099 citations
  5. 5Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity2021 · 1,105 citations